Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas.
Press
Oliver W
OW
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D019317:Evidence-Based Medicine; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy*; D009367:Neoplasm Staging; D016499:Radioimmunotherapy; D018714:Radiotherapy, Adjuvant; D012107:Research Design; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; C422802:ibritumomab tiuxetan